RxSight director granted 37,037 RSUs

Fountain Tamara reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Fountain Tamara reported acquisition or exercise transactions in this Form 4 filing.

RxSight, Inc. director Tamara Fountain received a grant of 37,037 shares of Common Stock in the form of restricted stock units (RSUs). This is a compensation-related award at no cash cost to her, not an open-market purchase.

Each RSU represents one share of RxSight common stock. All RSUs will vest together if she continues as an Outside Director until the earlier of the first anniversary of the June 17, 2026 grant date or the next annual stockholder meeting. After this award, she directly holds 72,582 shares.

Insider Trade Summary

Grant/Award: 37,037 shares

Grant/Award 1 txn

Insider Fountain Tamara

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	37,037	$0.00	$0.00

Holdings After Transaction: Common Stock — 72,582 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.
2. F2. Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026.

Key Figures

RSU grant size: 37,037 shares Grant price: $0.00 per share Total shares after grant: 72,582 shares +1 more

4 metrics

RSU grant size 37,037 shares Restricted stock units granted to director on June 17, 2026

Grant price $0.00 per share RSU award, compensation-based, not open-market

Total shares after grant 72,582 shares Direct holdings following the RSU award

Vesting trigger date Earlier of 1-year from June 17, 2026 or next annual meeting 100% vesting condition for RSU award

Key Terms

restricted stock unit ("RSU"), Outside Director, 2021 Equity Incentive Plan, Date of Grant

4 terms

restricted stock unit ("RSU") financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Outside Director financial

"Subject to the Reporting Person's continuing as an Outside Director through such applicable vesting date"

2021 Equity Incentive Plan financial

"Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan)"

Date of Grant financial

""Date of Grant" shall mean June 17, 2026."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RxSight (RXST) report for Tamara Fountain?

RxSight reported that director Tamara Fountain received a grant of 37,037 restricted stock units, each representing one share of common stock. The award is compensation-based and carries a zero dollar grant price per share, rather than being an open-market purchase.

How many RxSight (RXST) shares does Tamara Fountain hold after this grant?

Following the RSU grant, Tamara Fountain is reported as directly holding 72,582 shares of RxSight common stock. This total reflects the new award added to her existing position, as disclosed in the Form 4 insider transaction filing.

When do Tamara Fountain’s RxSight (RXST) RSUs vest?

All of Tamara Fountain’s RSUs vest 100% on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual meeting of stockholders. Vesting requires her continued service as an Outside Director through that applicable date.

What does each RxSight (RXST) RSU granted to Tamara Fountain represent?

Each restricted stock unit granted to Tamara Fountain represents a contingent right to receive one share of RxSight common stock. Actual delivery of shares occurs upon vesting, subject to her continuing to serve as an Outside Director through the specified vesting date.

Is Tamara Fountain’s RxSight (RXST) RSU grant an open-market stock purchase?

No, the 37,037-share RSU grant to Tamara Fountain is a compensation award with a grant price of $0.00 per share. It is classified as a grant or award acquisition, not an open-market buy transaction in RxSight stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fountain Tamara

(Last) (First) (Middle)

C/O RXSIGHT, INC.

100 COLUMBIA

(Street)

ALISO VIEJO CALIFORNIA 92656

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RxSight, Inc. [ RXST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	06/17/2026		A		37,037(2)	A	(1)	72,582	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

2. Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jim Schindler, as Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)